Fantastic presentation by Karim Fizazi! PEACE-1 at 7.7 years: adding abiraterone to ADT + docetaxel improved median OS to 6.2 vs 4.4 years (HR 0.68) in de novo mCSPC. Durable benef

Toni Choueiri, MD· @DrChoueiri · X·2026-10-24 16:30· 1 day agoScore70

Body · original

Fantastic presentation by Karim Fizazi! PEACE-1 at 7.7 years: adding abiraterone to ADT + docetaxel improved median OS to 6.2 vs 4.4 years (HR 0.68) in de novo mCSPC. Durable benefit from upfront intensification! @myESMO #ESMO26 @oncoalert

288 views · 9 likes · 4 reposts · 0 replies

Conference abstracts

2300TIPNCT07365995 NCT07365995 NCT07365995matched by Metastatic prostate cancer

BNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate, with investigator's choice of docetaxel or cabazitaxel in patients with metastatic castration-resistant prostate cancer

https://esmocongress.esmo.org

LBA15matched by Proffered paper 2: Breast cancer, early and advanced stage

Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study

https://esmocongress.esmo.org

NCT04884282NCT04884282matched by - **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

https://esmocongress.esmo.org

Source: Toni Choueiri, MD · x.com